Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HIV-1 Env VHH
- Development stage
- Preclinical
- Lead developer
- COGNANO
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Vaginal
01
Overview
COGNANO's anti-HIV-1 Env VHH is a preclinical-stage nanobody (single-domain antibody) designed to target the HIV-1 envelope (Env) protein. Developed using COGNANO's proprietary alpaca-derived VHH platform, this candidate aims to neutralize HIV-1 by binding to conserved epitopes on the Env glycoprotein, which is essential for viral entry into host CD4+ T cells. As a nanobody, it offers potential advantages over traditional monoclonal antibodies, including smaller size for better tissue penetration and the ability to access cryptic or recessed epitopes on the viral surface. It is currently being explored as a proof-of-concept therapeutic for HIV-1 infection and AIDS.
- Other names
- anti-Env VHHHIV-1 Env-VHHHIV1 Env-VHHHIV 1 Env-VHHanti-HIV-1 anti-Env VHH-COGNANO-HIV-1 Env-VHH antibody-nanobody-AIDS-HIV-1 infectionanti-HIV1 anti-Env VHH-COGNANO-HIV-1 Env-VHH antibody-nanobody-AIDS-HIV-1 infectionanti-HIV 1 anti-Env VHH-COGNANO-HIV-1 Env-VHH antibody-nanobody-AIDS-HIV-1 infection
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on anti-HIV-1 Env VHH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HIV-1 Env VHH.